CADL · Candel Therapeutics, Inc. · Executive Compensation
$8.64
+0.00 (+0.00%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$661.12M
Shares
76.52M
Volume · Oct 20
1.13M
Avg daily vol (3M)
1.17M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | M.D., Ph.D., FMedSci, Chief Executive Officer | $5,344,561 |
| Francesca Barone | M.D., Chief Scientific Officer | $1,561,536 |
| Charles Schoch | Chief Financial Officer | $1,470,817 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | M.D., Ph.D, FMedSci, Chief Executive Officer | $1,449,222 |
| Francesca Barone | M.D., Chief Scientific Officer | $726,222 |
| Seshu Tyagarajan | Ph.D., RAC Chief Technical and Development Officer | $613,231 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | M.D., Ph.D, FMedSci, Chief Executive Officer | $1,484,759 |
| Francesca Barone | M.D., Chief Scientific Officer | $706,876 |
| Jason A. Amello | Former Chief Financial Officer | $692,025 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | M.D., Ph.D, FMedSci, Chief Executive Officer | $1,844,971 |
| Seshu Tyagarajan | Ph.D., RACChief Technical and DevelopmentOfficer | $916,020 |
| Francesca Barone | M.D., Chief Scientific Officer | $908,302 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | M.D., Ph.D, FMedSci,Chief Executive Officer | $956,800 |
| Estuardo Aguilar-Cordova | M.D., inf., Ph.D., Founder and Former Chief Executive Officer and Chief Scientific Officer | $526,386 |
| John Canepa | Chief Financial Officer | $449,123 |
| Francesca Barone | M.D., Ph.D.Chief Scientific Officer | $364,797 |
| Seshu Tyagarajan | Ph.D., RACChief Technical and DevelopmentOfficer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Paul Peter Tak | M.D., Ph.D., FMedSci, President and Chief Executive Officer | $2,626,511 |
| John Canepa | Chief Financial Officer | $1,319,316 |
| Estuardo Aguilar-Cordova | M.D., inf., Ph.D., Founder and Former Chief Executive Officer and Chief Scientific Officer | $740,153 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Martine Zimmermann | Director | Appointed | 2026-09-10 |
| Charles Schoch | Chief Financial Officer | Appointed | 2025-06-23 |
| Maha Radhakrishnan, M.D. | member of the Board of Directors | Appointed | 2025-06-06 |
| Charles Schoch | interim Chief Financial Officer, principal financial officer and principal accounting officer | Appointed | 2024-01-12 |
| Jason A. Amello | Chief Financial Officer, principal financial officer and principal accounting officer | Resigned | 2024-01-12 |
| Jason A. Amello | Chief Financial Officer | Resigned | 2023-12-15 |
| Nicoletta Loggia, Ph.D., R.Ph. | director | Appointed | 2023-06-08 |
| Jason Amello | Chief Financial Officer | Appointed | 2022-09-07 |
| John Canepa | Chief Financial Officer | Resigned | 2022-09-07 |
| Joseph Papa | member of the Board of Directors | Appointed | 2022-08-01 |
| Gary Nabel | member of the Board of Directors | Appointed | 2022-08-01 |
| Renee Gaeta | member of the Board of Directors | Appointed | 2022-08-01 |
| Alan E. Smith | member of the Board of Directors | Resigned | 2022-08-01 |
| Udi Meirav | member of the Board of Directors | Resigned | 2022-08-01 |
| Shaan Gandhi | member of the Board of Directors | Resigned | 2022-08-01 |
Leadership
- Paul Peter Tak CEO, Board Member
- Charles Schoch CFO
- Jason Amello CFO
- Diem Nguyen, Ph.D. Board Member
- Edward J. Benz Board Member
- Gary Nabel Board Member
- Joseph Papa Board Member
- Maha Radhakrishnan Board Member
- Maha Radhakrishnan, M.D. Board Member
- Martine Zimmermann Board Member
- Nicoletta Loggia, Ph.D., R.Ph. Board Member
- Paul B. Manning Board Member